Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xeloda Adjuvant Colon Cancer sNDA Supports New Standard Of Care – Roche

Executive Summary

Roche's sNDA for use of Xeloda as adjuvant therapy for colon cancer supports use of the oncologic as a new standard of care for the indication, the company maintained

You may also be interested in...



Roche Keeps Lifecycle Management In Motion For Oncology Portfolio

The potential near-term approval of Roche/Genentech's Herceptin (trastuzumab) for adjuvant treatment of early-stage, HER2-positive breast cancer is one of several line extensions under the firms' aggressive lifecycle management of their partnered oncologics

Roche Keeps Lifecycle Management In Motion For Oncology Portfolio

The potential near-term approval of Roche/Genentech's Herceptin (trastuzumab) for adjuvant treatment of early-stage, HER2-positive breast cancer is one of several line extensions under the firms' aggressive lifecycle management of their partnered oncologics

Avastin Launch Unlikely To Affect Xeloda Sales, Roche Says

Early launch data from Genentech's Avastin indicate the oncologic will not affect Xeloda sales, Roche Worldwide Pharmaceuticals Head William Burns said

Related Content

Topics

UsernamePublicRestriction

Register

PS044593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel